Metoprolol Hexal (Metoprolol Succinate)

Metoprolol succinate blocks β1‑adrenergic receptors in the heart, decreasing the effects of sympathetic nervous system stimulation. This results in a slower heart rate, reduced contractility, and lower cardiac output, which together lower blood pressure and myocardial oxygen demand.

The appropriate dose of Metoprolol Hexal is individualized by the prescribing clinician based on the patient’s condition, response, and tolerability. Dosage may be adjusted over time, and patients should follow the prescriber’s instructions without self‑adjusting the amount.

Safety data for metoprolol succinate in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks with their healthcare provider.

To request Metoprolol Hexal, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs), and import documentation.

Metoprolol succinate is a cardio‑selective β1‑blocker, offering a favorable profile for patients with hypertension, angina, or heart failure. Compared with non‑selective agents such as propranolol, metoprolol has less impact on bronchial β2 receptors, making it a safer option for patients with mild respiratory disease.

Metoprolol Hexal tablets should be stored at room temperature, below 25 °C, in the original container to protect from moisture and light. Keep the product out of reach of children and do not use after the expiry date printed on the packaging.

Metoprolol Hexal is taken orally, usually as a whole tablet swallowed with water. It may be taken with or without food, but patients should follow the prescriber’s guidance on timing and whether the dose should be taken once daily or in divided doses.

Serious adverse events can include severe bradycardia, heart block, marked hypotension, bronchospasm in susceptible individuals, and rare cases of cardiogenic shock. Patients should seek immediate medical attention if they experience fainting, extreme fatigue, difficulty breathing, or a rapid change in heart rhythm.

Metoprolol Hexal is contraindicated in patients with known hypersensitivity to metoprolol or other beta blockers, those with severe bradycardia, second‑ or third‑degree atrioventricular block without a pacemaker, and individuals in cardiogenic shock. Caution is also advised for patients with uncontrolled asthma or severe peripheral vascular disease.